Design, synthesis, and preliminary pharmacological evaluation of 1,4- diazabicyclo[4.3.0]nonan-9-ones as a new class of highly potent nootropic agents

Journal of Medicinal Chemistry

Volumn 43, Issue 10, 2000, Pages 1969-1974

  Manetti, Dina ^a   Ghelardini, Carla ^a   Bartolini, Alessandro ^a   Bellucci, Cristina ^a   Dei, Silvia ^a   Galeotti, Nicoletta ^a   Gualtieri, Fulvio ^a   Romanelli, Maria Novella ^a   Scapecchi, Serena ^a   Teodori, Elisabetta ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAZABICYCLO[2.2.2]OCTANE; 1,4 DIAZABICYCLO[4.3.0]NONAN 9 ONE; ANIRACETAM; ETIRACETAM; FASORACETAM; NEBRACETAM; NEFIRACETAM; NOOTROPIC AGENT; OXIRACETAM; PIRACETAM; PRAMIRACETAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC SYSTEM; COGNITION; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; MOUSE; NERVE DEGENERATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PASSIVE AVOIDANCE; RECEPTOR AFFINITY; STRUCTURE ANALYSIS;

ADRENERGIC ALPHA-AGONISTS; AMNESIA; ANIMALS; AVOIDANCE LEARNING; BACLOFEN; CLONIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; GABA AGONISTS; MECAMYLAMINE; MICE; MOLECULAR STRUCTURE; MUSCARINIC ANTAGONISTS; NICOTINE; NOOTROPIC AGENTS; PIPERAZINES; PIRACETAM; PYRROLES; SCOPOLAMINE;

EID: 18344412429     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm991170t     Document Type: Article

References (27)

1. Giurgea, C.; Moeyersoons, F. E.; Evraerd, A. C. GABA-related hypothesis on the mechanism of action of the antimotion sickness drugs. Arch. Int. Pharmacodyn. 1967, 166, 238-251.
2. Gouliaev, A. H.; Senning, A. Piracetam and other structurally related nootropics. Brain Res. Rev. 1994, 19, 180-222.
3. Banfi, S.; Fonio, W.; Allievi, E.; Pinza, M.; Dorigotti, L. Cyclic GABA-GABA-B analogues IV. Activity on learning and memory. Il Farmaco (Ed. Sci.) 1984, 39, 16-22.
4. Nabeshima, T. Ameliorating effects of nefiracetam (DM-9384) on brain disfunction. Drugs Today 1994, 30, 357-379.
5. Nappi, G.; Rabasseda, X.; Mealy, N. Pramiracetam: a nootropic agent with improved efficacy in patients with senile or presenile cognitive impairment. Drugs Today 1994, 30, 469-482.
6. Rabasseda, X.; Mealy, N.; Presti, G. Aniracetam: a new nootropic drug with excellent tolerance for mild to moderate cognitive impairment in elderly people. Drugs Today 1994, 30, 9-24.
7. Prous, J.; Castagner, R. M.; Graul, A. Nebracetam fumarate. Drugs Future 1993, 18, 18-22.
8. Wolthuis, O. L. Behavioral effects of etiracetam in rats. Pharmacol. Biochem. Behav. 1989, 15, 247-255.
9. Wulfert, E.; Hanin, I.; Verloes, R. Facilitation of calcium-dependent cholinergic function by UCB L059, a second generation nootropic agent. Psychopharmacol. Bull. 1989, 25, 498-502.
10. Ciba-Geigy, A.-G. Preparation of piperazinylpyrrolidinone derivatives for treatment of amnesia and retention defects; JP 621, 185,068, Japan Kokai; Chem Abstr. 108, 167500y.
11. Graul, A.; Tracy, M.; Castaner, R. M. NS-105. Drugs Future 1997, 22, 639-640.
12. Mondadori, C. In search of the mechanism of action of the nootropics: new insights and potential clinical implications. Life Sci. 1994, 55, 2171-2178.
13. Pepeu, G.; Spignoli, G. Nootropic drugs and brain cholinergic mechanisms. Prog. Neuropsychopharmacol. Biol. Psychiat. 1989, 13 supp., 77-88.
14. Nabeshima, T.; Noda, Y.; Tohyama, K.; Itoh, J.; Kameyama, T. Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal disfunctions. Eur. J. Pharmacol. 1990, 178, 143-149.
15. Mondadori, C.; Ducret, T.; Borkowski, J. How long does "memory consolidation" take? New compounds can improve retention performance, even if administered up to 24 h after the learning experience. Brain Res. 1991, 555, 107-111.
16. Oyaizu, M.; Narahashi, T. Modulation of the neuronal nicotinic acetylcholine receptor channel by the nootropic drug nefiracetam. Brain Res. 1999, 822, 72-79.
17. Muller, W. E.; Eckert, G. P.; Eckert, A. Piracetam: novelty in a unique mode of action. Pharmacopsychiatry 1999, 32(s), 2-9.
18. Parnetti, L.; Senin, U.; Mecocci, P. Cognitive enhancement therapy for Alzheimer's disease. Drugs 1997, 53, 752-768.
19. Croisile, B.; Trillet, M.; Fondarai, J.; Laurent, B.; Mauguiare, F.; Billardon, M. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology 1993, 43, 301-305.
20. Coper, H.; Herrmann, W. M. Psychostimulants, analeptics, nootropics: an attempt to differentiate and assess drugs designed for the treatment of impaired brain functions. Pharmacopsychiatry 1988, 21, 211-217.
21. Pinza, M.; Farina, C.; Cerri, A.; Pfeiffer, U.; Riccaboni, M. T.; Banfi, S.; Biagetti, R.; Pozzi, O.; Magnani, M.; Dorigotti, L. Synthesis and pharmacological activity of a series of dihydro1H-pyrrolo(1,2-a)imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers. J. Med. Chem. 1993, 36, 4214-4220.
22. Altomare, C.; Carotti, A.; Casini, G.; Cellamare, S.; Ferappi, M.; Gavuzzo, E.; Mazza, F.; Pantaleoni, G.; Giorgi, R. Synthesis and cognition activating properties of some mono- and bicyclic lactam derivatives. J. Med. Chem. 1988, 31, 2153-2158.
23. Manetti, D.; Borea, P. A.; Ghelardini, C.; Gualtieri, F.; Romanelli, M. N.; Scapecchi, S.; Valle, G. Reduced-flexibility hybrids of the nicotinic agonists 1,1-dimethyl-4-acetylpiperazinium iodide and 2-(dimethylamino)methyl-5-cyclopentanone methiodide. Med. Chem. Res. 1997, 7, 301-312.
24. Jarvik, M. E.; Kopp, R. An improved one-trial passive avoidance learning situation. Psychol. Rep. 1967, 21, 221-224.
25. Cosentino, U.; Moro, G.; Pitea, D.; Todeschini, R.; Brossa, S.; Gualandi, F.; Scolastico, C.; Giannessi, F. Pharmacophore identification in amnesia reversal compounds using conformational analysis and chemometric methods. Quant. Struct. - Act. Relat. 1990, 9, 195-201.
26. Altomare, C.; Cellamare, S.; Carotti, A.; Casini, G.; Ferappi, M.; Gavuzzo, E.; Mazza, F.; Carrupt, P.-A.; Gaillard, P.; Testa, B. X-ray crystal structure, partitioning behaviour, and molecular modeling study of piracetam-type nootropics: insights into the pharmacophore. J. Med. Chem. 1995, 38, 170-179.
27. Nylen, P. Beitrag zur Kenntnis der Organischen Phosphorverbindungen. (Contribution to the knowledge of organic phosphorous compounds.) Berichte 1924, 57, 1023-1038.